Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer

BackgroundDespite significant benefits from targeted therapy in patients with driver mutations, inevitable drug resistance usually occurred in non-small cell lung cancer, highlighting the necessity for sequential treatments to prolong overall survival. Unfortunately, durable drug response has not be...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Yongkuan Guo, Ran Zhang, Yiran Meng, Li Wang, Liuqing Zheng, Jian You
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	ensartinib EML4-ALK osimertinib resistance mechanism case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1359403/full